Innate Pharma S.A. (IPHA)
| Bid | 1.92 |
| Market Cap | 164.27M |
| Revenue (ttm) | 33.79M |
| Net Income (ttm) | -34.05M |
| EPS (ttm) | -0.69 |
| PE Ratio (ttm) | -2.84 |
| Forward PE | 2.79 |
| Analyst | Buy |
| Ask | 2.05 |
| Volume | 811 |
| Avg. Volume (20D) | 238,222 |
| Open | 1.96 |
| Previous Close | 1.91 |
| Day's Range | 1.96 - 1.96 |
| 52-Week Range | 1.29 - 3.51 |
| Beta | 0.95 |
About IPHA
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizu...
Analyst Forecast
According to 1 analyst ratings, the average rating for IPHA stock is "Buy." The 12-month stock price forecast is $11.5, which is an increase of 486.73% from the latest price.
Stock Forecasts
2 weeks ago · businesswire.com
Innate Pharma Reports Full Year 2024 Financial Results and Business UpdateMARSEILLE, France--(BUSINESS WIRE)-- #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the y...
1 month ago · seekingalpha.com
Innate: Lacutamab Treatment Program Moves Forward With Potential ExpansionPositive results achieved in the open-label phase 2 TELLOMAK study, using lacutamab for the treatment of patients with relapsed/refractory Sezary Syndrome; Patients achieved a confirmed Objective Resp...